Phase 1Recruiting
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
A Two-Part, Phase 1, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and WISPER Target Engagement of HTX-001 in Adult Healthy Participants (Part 1) and in Adult Participants With Nonobstructive Hypertrophic Cardiomyopathy (Part 2)
- Sponsor
- Haya Therapeutics, Inc. (Industry)
- Enrolment
- 10 planned
- Conditions
- Nonobstructive Hypertrophic Cardiomyopathy
- Interventions
- HTX-001
- Ages
- adults, older adults
- Registry
- NCT07867288
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HTX-001 in human adult participants.
Primary outcomes
- Safety and Tolerability
History
Primary completion expected
Started
Last registry update
Registered